fbpx

QQQ
+ 2.31
364.32
+ 0.63%
BTC/USD
+ 686.58
62214.91
+ 1.12%
DIA
+ 3.70
345.43
+ 1.06%
SPY
+ 3.26
439.24
+ 0.74%
TLT
-0.85
146.73
-0.58%
GLD
-2.66
170.66
-1.58%

Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader

by
May 2, 2018 10:10 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Impax Laboratories Inc (NASDAQ:IPXL) announced an agreement in October to merge with privately held Amneal Pharma, with 75 percent of the combined company held by Amneal shareholders and 25 percent by Impax Labs shareholders.

The FTC recently laid down conditions — including the divestiture of Impax's rights and assets for 10 products to three other companies — while giving its OK for the proposed combination.

The Analyst

Barclays analyst Douglas Tsao initiated coverage of Impax Labs with an Outperform rating and $27 price target.

The Thesis

Impax Labs' pending merger with Amneal is likely to result in "a generics market leader positioned to deliver attractive growth," Tsao said in a Tuesday note.

"The idea of a 'growth' story in generics might strike some as an anachronism, understandable givent he disruption seen in the U.S. market over the last two years, but we see the opportunity for shareholders reaping the benefits of Amneal's investment in R&D to drive attractive top-line growth," the analyst said. 

The expected leadership of two generics- industry stalwarts, Rob Stewart and Paul Bisaro, increases Barclays' confidence in the proposed combination, Tsao said. 

Apart from executing on the existing pipeline, the analyst projects that the executives will rejuvenate the company's Paragraph IV strategy. The term refers to a certification given to a generics company that files its abbreviated new drug application first and secures market exclusivity for 180 days.

The leadership also increases confidence in the execution of merger integration and delivery on synergy targets, Tsao said. 

Barclays sees several attractive assets in Amneal's pipeline, including Copaxone, biosimilars filgrastim and pegfilgrastim.

"We expect the company to pursue opportunities within generics or even down the value chain including OTC," the analyst said. 

The Price Action

Impax Labs shares have gained 19 percent year-to-date.

The stock was up 1.26 percent at the time of publication Wednesday. 

Related Links:

Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Cantor Out With Note On Endo, Says Oxymorphone Subpoena May Not Hurt That Much And Is Isolated To Endo For Now, But More Co.'s Could Be The Target To Investigations Over Time Including Teva, Mylan, Impax, Mallinckrodt, Allergan

Cantor Out Positive On Impax, Says Amneal's Approval Of Triamcinolone Acetonide Injection Bridges Gap Between Co.'s Guidance For Acquisition Of Amneal And Sales Trends Over First 9 Mo. For Both Comanches, Says This Has Been An Overhand On Stock

More Pros Than Cons Investing In Impax Right Now

Evercore Out With Color On Mylan, Says EpiPen Competitors Appear To Be Having An Impact, Specifically Impax